Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20106 in MDS Anemia
NCT06594965Phase 2Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Oct 2024
- Primary completion
- Oct 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of elritercept in myelodysplastic syndrome (MDS), sponsored by Hansoh Pharmaceutical Group. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
elritercept
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06594965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06594965.